Hester Biosciences Ltd's Q3FY25 Quarter Results
- 31 Jan 2025
Result Summary
- Hester Biosciences Ltd reported a 17.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 4.5%.
- Its expenses for the quarter were down by 21.4% QoQ and 6.6% YoY.
- The net profit increased 36.0% QoQ and increased 183.8% YoY.
- The earnings per share (EPS) of Hester Biosciences Ltd stood at 13.4 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 71.03 | 85.53 | 67.97 | -17.0% | 4.5% |
Total Expenses | 58.64 | 74.62 | 62.77 | -21.4% | -6.6% |
Profit Before Tax | 12.39 | 10.91 | 5.20 | 13.6% | 138.3% |
Tax | 1.96 | 3.48 | 2.39 | -43.7% | -18.0% |
Profit After Tax | 11.41 | 8.39 | 4.02 | 36.0% | 183.8% |
Earnings Per Share | 13.40 | 9.90 | 4.70 | 35.4% | 185.1% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Hester Biosciences Ltd is a prominent player in the animal healthcare sector, specializing in the production and distribution of vaccines and health products for animals. Its primary focus is on providing comprehensive solutions for poultry and livestock health, which includes biologicals, pharmaceuticals, and disinfectants. With a strong presence in the Indian market and expanding international operations, Hester Biosciences continues to innovate in the field of animal health. The company is known for its emphasis on research and development, which has led to a robust pipeline of veterinary products. While specific recent developments are not provided, the company is typically engaged in expanding its product lines and market reach.
Revenue
For the third quarter of the fiscal year 2025 (Q3FY25), Hester Biosciences Ltd reported a total income of ₹71.03 crores. This represents a decrease of 17.0% from the previous quarter (Q2FY25) where the total income was ₹85.53 crores. However, compared to the same quarter in the previous year (Q3FY24), which recorded a total income of ₹67.97 crores, there is an increase of 4.5%. These figures indicate fluctuations in the company's revenue generation over the quarters and year-over-year growth in its income.
Profitability
In terms of profitability, the company reported a profit before tax of ₹12.39 crores for Q3FY25, which is an increase of 13.6% compared to Q2FY25, where the profit before tax stood at ₹10.91 crores. Year-over-year, there is a significant increase of 138.3% when compared to Q3FY24, which had a profit before tax of ₹5.20 crores. The profit after tax for Q3FY25 is ₹11.41 crores, marking a 36.0% increase from the previous quarter's ₹8.39 crores and a substantial 183.8% rise from the ₹4.02 crores recorded in Q3FY24. Earnings per Share (EPS) for Q3FY25 is ₹13.40, up by 35.4% from Q2FY25's ₹9.90 and 185.1% from Q3FY24's ₹4.70. These metrics suggest a strong improvement in the company's profitability over the period under review.
Operating Metrics
The total expenses for Hester Biosciences Ltd in Q3FY25 were ₹58.64 crores, which is a decrease of 21.4% from Q2FY25’s ₹74.62 crores and a decrease of 6.6% compared to Q3FY24's ₹62.77 crores. The tax expenditure for Q3FY25 was ₹1.96 crores, which is 43.7% lower than Q2FY25's ₹3.48 crores and 18.0% lower than the ₹2.39 crores recorded in Q3FY24. These figures reflect changes in the company's operating expenses and taxation over the quarters.
